PANTERA

PanTera is dedicated to securing the large-scale production of actinium-225 (225Ac), a highly promising alpha-emitting radioisotope crucial for advancing Targeted RadioTherapy (TRT) in the fight against cancer. Located in Mol, Flemish Region, PanTera's mission is to enhance the accessibility of future innovative cancer therapies rooted in 225Ac and theranostics on a global scale. The company operates from its primary address at Boeretang 200, Mol, Flemish Region 2400, BE.

With a focus on improving cancer treatment options, PanTera is positioned to play a pivotal role in the pharmaceutical manufacturing sector. The company is committed to driving innovation and ensuring that cutting-edge treatments reach those who need them most. Through strategic partnerships and a commitment to research and development, PanTera strives to make a significant impact on the landscape of cancer therapy.

PanTera aims to be at the forefront of cancer treatment innovation. We invite the manager of PanTera to create a customized and exclusive company showcase and product listing on our platform to further highlight PanTera’s contributions to the pharmaceutical industry and its dedication to improving patient outcomes.